The role of the intestinal microbiota in diagnosing and treating pancreatic diseases is increasingly significant, with fecal microbiota transplantation (FMT) emerging as a promising therapeutic approach for conditions such as pancreatic cancer, pancreatitis, and type 1 diabetes (T1D). FMT involves transferring gut microbiota from healthy donors to patients with pancreatic disorders to restore intestinal balance and alleviate symptoms. Recent research highlights the therapeutic benefits of targeting the gut microbiota for personalized interventions in pancreatic disorders. However, further investigation is needed to understand the complex interactions between gut microbiota and pancreatic physiology. FMT has shown potential in treating pancreatic disorders by modulating the microbiota to normalize it and improve patient outcomes. Studies indicate that microbiota changes are associated with pancreatic diseases, including pancreatic ductal adenocarcinoma, acute and chronic pancreatitis, and T1D. The microbiota-pancreas axis, involving bidirectional communication between the pancreas and intestinal microbiota, plays a crucial role in pancreatic immunity and disease pathogenesis. FMT has been shown to reduce inflammatory responses and may serve as a radioprotective agent in cancer treatment. Research also suggests that the gut microbiota influences the progression of pancreatic cancer, with certain bacteria potentially acting as biomarkers. FMT has shown promise in treating acute and chronic pancreatitis by restoring gut microbiota balance and reducing inflammation. In T1D, FMT may help restore gut microbiota balance and potentially slow disease progression. While FMT is generally safe, further research is needed to determine its long-term efficacy and safety in treating pancreatic disorders. The potential of FMT as a personalized treatment for pancreatic diseases is promising, with ongoing studies exploring its application in various conditions.The role of the intestinal microbiota in diagnosing and treating pancreatic diseases is increasingly significant, with fecal microbiota transplantation (FMT) emerging as a promising therapeutic approach for conditions such as pancreatic cancer, pancreatitis, and type 1 diabetes (T1D). FMT involves transferring gut microbiota from healthy donors to patients with pancreatic disorders to restore intestinal balance and alleviate symptoms. Recent research highlights the therapeutic benefits of targeting the gut microbiota for personalized interventions in pancreatic disorders. However, further investigation is needed to understand the complex interactions between gut microbiota and pancreatic physiology. FMT has shown potential in treating pancreatic disorders by modulating the microbiota to normalize it and improve patient outcomes. Studies indicate that microbiota changes are associated with pancreatic diseases, including pancreatic ductal adenocarcinoma, acute and chronic pancreatitis, and T1D. The microbiota-pancreas axis, involving bidirectional communication between the pancreas and intestinal microbiota, plays a crucial role in pancreatic immunity and disease pathogenesis. FMT has been shown to reduce inflammatory responses and may serve as a radioprotective agent in cancer treatment. Research also suggests that the gut microbiota influences the progression of pancreatic cancer, with certain bacteria potentially acting as biomarkers. FMT has shown promise in treating acute and chronic pancreatitis by restoring gut microbiota balance and reducing inflammation. In T1D, FMT may help restore gut microbiota balance and potentially slow disease progression. While FMT is generally safe, further research is needed to determine its long-term efficacy and safety in treating pancreatic disorders. The potential of FMT as a personalized treatment for pancreatic diseases is promising, with ongoing studies exploring its application in various conditions.